<DOC>
	<DOCNO>NCT00702351</DOCNO>
	<brief_summary>To evaluate induction multiple follicular growth single dose administration 100 μg 150 μg Org 36286 long protocol GnRH agonist .</brief_summary>
	<brief_title>A Trial Single Dose Corifollitropin Alfa 's Ability Induce Multiple Follicular Growth During First Week Controlled Ovarian Stimulation IVF ICSI ( 38833 ) ( P05788 )</brief_title>
	<detailed_description>In trial , subject ( pre ) treat daily subcutaneous triptorelin , GnRH agonist know provide profound suppression endogenous LH FSH . It evaluate whether down-regulated subject show appropriate ovarian response 100 μg 150 μg Org 36286 first week stimulation . To evaluate , follicular growth measure USS , serum inhibin-B E2 level assess .</detailed_description>
	<criteria>Females couple indication control ovarian stimulation ( COS ) IVF ICSI least one previous COS cycle proven normal ovarian response ; &gt; =18 &lt; = 39 year age time sign informed consent ; . First group : Body weight &gt; = 50 kg BMI &gt; = 18 &lt; = 29 kg/m^2 ; b . Second group : Body weight &lt; = 60 kg BMI &lt; = 29 kg/m^2 ; Normal menstrual cycle length : 2435 day ; Ejaculatory sperm ( use donate and/or cryopreserved sperm allow ) ; Normal routine diagnostic hysteroscopy endometrial biopsy ; Willing able sign inform consent . History current ( treat ) endocrine abnormality ; History ovarian hyperresponse1 history ovarian hyperstimulation syndrome ( OHSS ) ; History current polycystic ovary syndrome ( PCOS ) ; A basal antral follicle count &gt; 20 ( size &lt; 11 mm , ovary combine ) USS early follicular phase ( menstrual cycle day 25 ) ; Less 2 ovary ovarian abnormality ; Presence unilateral bilateral hydrosalpinx ( visible USS ) ; Presence unilateral bilateral endometriomas ( &gt; 10 mm ; visible USS ) ; More three unsuccessful COS cycle since last establish ongoing pregnancy ( applicable ) ; History non low ovarian response FSH/hMG treatment ; FSH LH &gt; 12 IU/L measure local laboratory ( sample take early follicular phase : menstrual cycle day 25 ) ; Any clinically relevant abnormal laboratory value base sample take screening phase ; Contraindications use gonadotropin ( e.g . tumor , pregnancy/lactation , undiagnosed vaginal bleeding , hypersensitivity , ovarian cyst ) GnRH analogue ( e.g . hypersensitivity , pregnancy/lactation ) ; Recent history current epilepsy , diabetes cardiovascular , gastrointestinal , hepatic , renal pulmonary disease ; History presence alcohol drug abuse within 12 month prior sign informed consent ; Previous use Org 36286 ; Use hormonal preparation within 1 month prior screen ; Administration investigational drug within three month prior sign inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Infertility</keyword>
	<keyword>Pharmacological effect drug</keyword>
	<keyword>Drug therapy</keyword>
	<keyword>Hormones</keyword>
	<keyword>GnRH agonist</keyword>
	<keyword>RecFSH</keyword>
	<keyword>Corifollitropin alfa</keyword>
	<keyword>Open-label</keyword>
</DOC>